Knockdown of Mageb16 disrupts cell proliferation and lineage specification during mouse preimplantation development

Xiaoqing Wu1, Xin Ming1, Qing Liu1

  • 1Anhui Province Key Laboratory of Embryo Development and Reproductive Regulation, Anhui Province Key Laboratory of Pollution Damage and Biological Control for Huaihe River Basin, Fuyang Normal University, Fuyang City, Anhui Province, 236037, PR China.

Theriogenology
|March 21, 2025
PubMed

Insights

Melanoma antigen family member B16 (Mageb16) is vital for early mouse embryo development. Its knockdown impairs blastocyst formation, cell cycle progression, and lineage segregation.

Area of Science:

  • Developmental biology
  • Epigenetics
  • Molecular biology

Background:

  • Melanoma antigen family member B16 (Mageb16) is known for its role in embryonic stem cell pluripotency.
  • Its function during the critical preimplantation development stage is not well understood.

Purpose of the Study:

  • To investigate the expression pattern and biological significance of Mageb16 during mouse preimplantation development.
  • To elucidate Mageb16's role in early embryonic cell proliferation and lineage specification.

Main Methods:

  • Quantitative analysis of Mageb16 mRNA expression during preimplantation development.
  • Small interfering RNA (siRNA) mediated knockdown of Mageb16 in mouse embryos.
  • Assessment of blastocyst formation, cell number, cell cycle progression, and histone modifications.

Main Results:

  • Mageb16 mRNA expression peaked at the morula stage.
  • Mageb16 knockdown significantly reduced blastocyst and outgrowth formation rates and total cell count.
  • Mageb16 reduction caused G2/M cell cycle arrest and disrupted lineage segregation without inducing DNA damage.
  • Knockdown led to increased H3K27ac levels but attenuated overall transcriptional activity.

Conclusions:

  • Mageb16 plays a critical role in mouse preimplantation development.
  • Mageb16 likely regulates cell proliferation and lineage specification through epigenetic mechanisms.